Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill

 
• By Derrick Gingery
shared biosimilar exclusivity
Sponsors may be confused by the statutory language governing first interchangeable exclusivity and whether multiple first filers could share it. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

More from Biosimilars

More from Products